Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|18|4|303-308

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.18, Iss.4, 2017-05, pp. : 303-308

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Chronic kidney disease (CKD) is an important health problem, because of unsuccessful outcomessuch as CKD progression to end stage renal disease and high risk of cardiovascular disease(CVD). Anemia, associated with CKD, is considered a non-traditional risk factor for CVD which maycontribute to faster CKD progression. Anemia treatment with erythropoiesis-stimulating agents (ESAs)seems to exert non-hematopoietic effects on different tissues and organs, including cardiovascular systemand kidneys. On the other hand, clinical use of high doses of short-acting ESAs and higher targethemoglobin level were associated with higher risk of CVD. Literature data indicate the usefulness oflong-acting ESAs in treatment of anemia in non-dialysis CKD patients. In particular, continuouserythropoietin receptor activator seems to be a good choice in these patients because of its efficiency,safety and monthly administration. Continuous but slower erythropoietin receptor activation, usingmethoxy polyethylene glycol-epoetin beta (MPG-EPO), administered once a month, slowly correctsanemia without exceeding the recommended hemoglobin level. An overview of the available literaturemay suggest nephroprotective and cardiovascular protective effects of MPG-EPO. It seems possiblethat anemia treatment with a novel ESAs, MPG-EPO in early stages of CKD may reduce CVD risk inthese patients and delay CKD progression. This review of available literature evaluates the correlationbetween continuous erythropoietin receptor activation using MPG-EPO and CKD progression andCVD risk in non-dialysis CKD patients.